Fexapotide triflutate: results of long‑term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement.
Shore et al. World Journal of Urology. 2018;36(5):801-9.
Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia.
Shore et al. Therapeutic Advances in Urology. 2019;11:1-16.